3HP 2827
Alternative Names: 3HP-2827Latest Information Update: 06 Sep 2024
At a glance
- Originator 3H Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Jun 2024 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Metastatic disease) in China (PO) (NCT06378593)
- 22 Apr 2024 3H Pharmaceuticals plans a phase I/II trial for Solid tumors (Unresectable/Inoperable, Metastatic disease, Late-stage disease) in China (PO) in June 2024 (NCT06378593)
- 14 Mar 2024 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the American Association for Cancer Research, 2024 (AACR-2024)